The authors concluded that the physiochemical and biological analyses demonstrated that the biosimilar is not affected by reconstitution, dilution, and extended storage in infusion bags. These findings, they write, provide added reassurance to healthcare providers that the biosimilar is safe and effective under extended in-use conditions.
European-approved biosimilar infliximab, Zessly (also approved in the United States as Ixifi), has undergone extensive stability and in-use testing to ensure that its quality is robust, but regulatory requirements do not stipulate extended in-use handling. A study recently published in Drugs in R&D sought to provide healthcare providers with information on the stability of the biosimilar in extended in-use conditions after dilution and reformulation for intravenous administration.
In the study, 55 vials of the biosimilar were produced under aseptic conditions, and reconstitution and dilution were performed in line with good manufacturing practice in a laboratory. In total, 33 of the vials were reconstituted for storage at 5°C (± 3°C) for up to 30 days or 25°C  (± 2°C) at a relative humidity of 60% (± 5%) for up to 14 days, which were considered worst-case handling conditions.
An additional 22 vials were reconstituted for dilution. Vials of the antibody were diluted in 250 mg polyethylene bags to obtain 2 concentrations: 0.4 mg/mL and 4.0 mg/mL. One bag of each concentration was stored for up to 30 the same temperatures and relative humidity as described above.
When sampled, osmolality, pH, and clarity all met predefined acceptance criteria, with no changes observed at dilution or storage. There were no changes in subvisible particle content across batches, solutions, storage conditions, or storage durations. No notable changes in protein concentration were observed over time across batches or storage conditions.
Absence of changes in ultraviolet absorption indicated minimal protein aggregation, precipitation, and adsorption under in-use conditions, and all results met predefined criteria.
No significant difference in charge variants were identified. There were also no changes in high-molecular-weight variants. The abundance of fragments was low, and the purity was high across batches and storage conditions.
Analysis of bioassay data for the samples showed no changes in potency, and all results were within assay variability limits and met predefined criteria.
The authors concluded that the physiochemical and biological analyses demonstrated that the biosimilar is not affected by reconstitution, dilution, and extended storage in infusion bags. These findings, they write, provide added reassurance to healthcare providers that the biosimilar is safe and effective under extended in-use conditions.
Reference
Vimpolsek M, Gottar-Guillier M, Rossy E. Assessing the extended in-use stability of the infliximab biosimilar PF-06438179/GP1111 following preparation for intravenous infusion [published February 27, 2019]. Drugs R D. doi: 10.1007/s40268-019-0264-1.
Eye on Pharma: EU Ustekinumab Approval; New Golimumab Data; Evernorth Adds Humira Biosimilar
April 29th 2024The European Union gained a new ustekinumab biosimilar; Alvotech released positive results from a clinical trial evaluating a golimumab biosimilar and the reference products (Simponi and Simponi Aria), and Evernorth announced that it is set to cover an adalimumab biosimilar at zero cost to patients.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
What Clinicians Need to Know About Using Biosimilars to Treat IBD
April 13th 2024A review article, intended to act as a guide for clinicians, summarizes the available infliximab and adalimumab biosimilars for treating inflammatory bowel disease (IBD) as well as others that are coming down the pipeline.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.